Clinical trial · Interventional
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors - a Randomized Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immune Checkpoint Inhibitors | Drug | — | UNRESOLVED |
| Immune checkpoint inhibitors plus Iscador® Qu. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm A: Immune checkpoint inhibitors plus Iscador® Qu
- description
- Patients randomized to Arm A will be treated with Immune checkpoint inhibitors plus Iscador® Qu.
- interventionNames
- Drug: Immune checkpoint inhibitors plus Iscador® Qu.
- type
- ACTIVE_COMPARATOR
- label
- Arm B: Immune checkpoint inhibitors
- description
- Patients randomized to Arm B will be treated with Immune checkpoint inhibitors only.
- interventionNames
- Drug: Immune Checkpoint Inhibitors
Primary outcomes (5)
- measure
- Percentage of patients with a relative increase in T cell richness or diversity of 20% or more
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced non-operable or metastatic solid tumor, except for skin cancer * Eligible for routine (standard) treatment with immune checkpoint inhibitor (+/- chemo/targeted therapy) as per the discretion of the local investigator * Subjects must be eligible for treatment with mistletoe preparations (controlled brain metastases, prednisolone equivalent below 10mg, no known hypersensitivity) * ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2 * Males and Females at least 18 years of age; no subjects under tutelage * No previous mistletoe treatment Exclusion Criteria: * Contraindications to Iscador® Qu or immune checkpoint inhibitors, e.g. hypersensitivity, active autoimmune disorder * Patients with skin cancer * Participation in another study with investigational drug within 30 days prior to enrolment (participation in observational studies or diagnostic studies without a particular drug intervention are allowed) * Enrolment of the investigator, his/her family members, employees and other dependent
References
Publications (0)
Data not yet available